List view / Grid view
12 May 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced in August 2011 that the Group company, Kitasato Daiichi Sankyo Vaccine Company Limited, had been selected for the Japanese Ministry of Health, Labour and Welfare’s cell culture vaccine production facility capacity building grant...
12 May 2014 | By Novo Nordisk
Novo Nordisk announced new phase 3 interim data from its guardian™2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade...
12 May 2014 | By Merck
ZONTIVITY added to standard of care demonstrated long-term benefit through three years...
12 May 2014 | By Biogen Idec
Biogen Idec announced that Richard (Rick) A. Rudick, M.D., has joined the company as vice president, Development Sciences, Value-Based Medicine...
12 May 2014 | By AstraZeneca
Study evaluating novel investigational IL-17 receptor antibody meets all primary and secondary endpoints...
12 May 2014 | By Abbott
Early study results suggest Abbott technology equivalent to current standard of care, but produces results much more quickly...
12 May 2014 | By European Pharmaceutical Review
European Drug Target Review is a business-to-business magazine featuring the latest developments in drug discovery and new drug development collaborations...
8 May 2014 | By Boehringer Ingelheim
Details of a new 6,000 patient study of dabigatran etexilate were announced at the European Stroke Conference, Nice, France...
8 May 2014 | By AbbVie
AbbVie submitted marketing authorization applications to the European Medicines Agency seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus infection...
8 May 2014 | By Johnson & Johnson
Filing Includes data from treatment-naïve patients with advanced fibrosis and null responders with all stages of liver fibrosis...
7 May 2014 | By kdm communications
Quotient Clinical has announced the extension of its Translational Pharmaceutics™ platform into patient-focused cancer drug development...
7 May 2014 | By Johnson & Johnson
Demonstrated significant efficacy in manic and depressive mood symptoms and psychosis, and improved patient functioning...
7 May 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced that Brian Daniels, senior vice president, Global Development and Medical Affairs, will be retiring from the company...
7 May 2014 | By Boehringer Ingelheim
Details of a new 6,000 patient study of dabigatran etexilate were announced at the European Stroke Conference...
6 May 2014 | By H. Lundbeck A/S
H. Lundbeck A/S has once again received support and recognition for its research on Parkinson’s disease through a grant from The Michael J. Fox Foundation for Parkinson’s Research...
